Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum10844310.26442/20751753.2022.2.201512ArticlesСтатьиReview ArticleCOVID-associated cognitive impairments: A reviewCOVID-ассоциированные когнитивные нарушенияhttps://orcid.org/0000-0002-9097-898XPreobrazhenskayaIrina S.ПреображенскаяИрина Сергеевна
Russian Federation

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University (Sechenov University)

д-р мед. наук, проф. каф. нервных болезней и нейрохирургии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)

irinasp2@yandex.ruSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)15022022242961020106202201062022Copyright ©; 2022, Consilium MedicumCopyright ©; 2022, ООО "Консилиум Медикум"2022Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/108443

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, began in March 2020 and continues to the present. The virus most often affects the respiratory system; to date, there is evidence of possible damage to the heart, skin, kidneys, central nervous system in this disease. In this regard, it is of great interest to study the neurological features of COVID-19, in particular, the development of cognitive disorders or the increase in the severity of already existing cognitive impairments. This review provides the latest data on the relationship of COVID-19 and cognitive impairment, the proposed etiology, pathogenesis and main clinical manifestations of cognitive disorders, and also discusses possible strategies for the treatment of cognitive impairment after suffering COVID-19.

Пандемия COVID-19, вызванная вирусом SARS-CoV-2, началась в марте 2020 г. и продолжается по настоящее время. Вирус чаще всего поражает дыхательную систему; на сегодняшний день есть данные о возможном поражении сердца, кожи, почек, центральной нервной системы при этом заболевании. В связи с этим большой интерес представляет изучение неврологических особенностей COVID-19, в основном – развития когнитивных расстройств или усиления выраженности уже существующих когнитивных нарушений. В настоящем обзоре приводятся последние данные о взаимосвязи COVID-19 и когнитивных нарушений, предположительная этиология, патогенез и основные клинические проявления когнитивных расстройств, а также обсуждаются возможные стратегии лечения когнитивных нарушений после перенесенного COVID-19.

COVID-19SARS-CoV-2cognitive impairmentelderly patientsMoCaMMSEexecutive functionsfatigueemotional disturbancesdepressionendothelial dysfunctionvascular cognitive impairmentAlzheimer's diseasemild cognitive impairmenttreatmentnicergolinesermionCOVID-19SARS-CoV-2когнитивные нарушенияпожилые пациентыМоСаMMSEуправляющие функцииусталостьэмоциональные нарушениядепрессияэндотелиальная дисфункциясосудистые когнитивные нарушенияболезнь Альцгеймераумеренные когнитивные расстройствалечениеницерголинсермионTarantola D, Dasgupta N. COVID-19 Surveillance Data: A Primer for Epidemiology and Data Science. Am J Public Health. 2021;111(4):614-9. DOI:10.2105/AJPH.2020.306088Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239-42. DOI:10.1001/jama.2020.2648Tsai ST, Lu MK, San S, Tsai CH. The neurologic manifestations of Coronavirus disease 2019 pandemic: a systemic review. Front Neurol. 2020;11:498. DOI:10.3389/fneur.2020.00498Pinzon RT, Wijaya VO, Buana RB, et al. Neurologic characteristics in Coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Neurol. 2020;11:565. DOI:10.3389/fneur.2020.00565Pajo AT, Espiritu AI, Apor ADAO, Jamora RDG. Neuropathologic findings of patients with COVID-19: a systematic review. Neurol Sci. 2021;42(4):1255-66. DOI:10.1007/s10072-021-05068-7Kantonen J, Mahzabin S, Mäyränpää MI, et al. Neuropathologic features of four autopsied COVID-19 patients. Brain Pathol. 2020;30(6):1012-6. DOI:10.1111/bpa.12889Fabbri VP, Foschini MP, Lazzarotto T, et al. Brain ischemic injury in COVID-19-infected patients: a series of 10 post-mortem cases. Brain Pathol. 2021;31(1):205-10. DOI:10.1111/bpa.12901Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological Features of COVID-19. N Engl J Med. 2020;383(10):989. DOI:10.1056/NEJMc2019373Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919-29. DOI:10.1016/S1474-4422(20)30308-2Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415-24. DOI:10.1084/jem.20050828Bodro M, Compta Y, Sánchez-Valle R. Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):e923. DOI:10.1212/NXI.0000000000000923Parra JED, Montoya DD, Peláez FJC. COVID-19 also Affects the Nervous System by One of its Gates: The Vascular Organ of Lamina Terminalis and the Olfactory Nerve. Neurological Alert, Dysosmia or Anosmia Test Can Help to A Quick Diagnosis. Int J Odontostomat. 2020;14(3):285-7. DOI:10.4067/S0718-381X2020000300285Jiao L, Yang Y, Yu W, et al. The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys. Sig Transduct Target Ther. 2021;6:169. DOI:10.1038/s41392-021-00591-7Frontera JA, Boutajangout A, Masurkar AV, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer’s dementia. Alzheimer’s Dement. 2022;89(3):610-6. DOI:10.1002/alz.12556Sutter R, Hert L, De Marchis GM, et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann Neurol. 2021;89(3):610-6. DOI:10.1002/ana.26004Aamodt AH, Høgestøl EA, Popperud TH, et al. Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. J Neurol. 2021;268(10):3574-83. DOI:10.1007/s00415-021-10517-6Prudencio M, Erben Y, Marquez CP, et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci Transl Med. 2021;13. DOI:10.1126/scitranslmed.abi7643Sun B, Tang N, Peluso MJ, et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells. 2021;10(2):386. DOI:10.3390/cells10020386Altuna M, Sánchez-Saudinós MD, Lleó A. Cognitive symptoms after COVID-19. Neurology perspectives. 2021;1:16-24. DOI:10.1016/j.neurop.2021.10.005Vanderlind WM, Rabinovitz BB, Miao IY, et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment. Curr Opin Psychiatry. 2021;34:420-33. DOI:10.1097/YCO.0000000000000713Almeria M, Cejudo JC, Sotoca J, et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163. DOI:10.1016/j.bbih.2020.100163Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268-70. DOI:10.1056/NEJMc2008597Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020;129:98-102. DOI:10.1016/j.jpsychires.2020.06.022Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784. DOI:10.1371/journal.pone.0240784Poyiadji N, Shahin G, Noujaim D, et al. COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020;296(2):E119-20. DOI:10.1148/radiol.2020201187Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55-8. DOI:10.1016/j.ijid.2020.03.062Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382:e60. DOI:10.1056/NEJMc2009787Lyden P. Temporary Emergency Guidance to US Stroke Centers During the Coronavirus Disease 2019 (COVID-19) Pandemic. Stroke. 2020;51(6):1910-2. DOI:10.1161/STROKEAHA.120.030023Ntaios G, Pearce LA, Veltkamp R, et al. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke. 2020;51(6):1797-804. DOI:10.1161/STROKEAHA.119.028669Ahmadi Karvigh S, Vahabizad F, Banihashemi G, et al. Ischemic Stroke in Patients with COVID-19 Disease: A Report of 10 Cases from Iran. Cerebrovasc Dis. 2021;50(2):239-44. DOI:10.1159/000513279Cavallieri F, Marti A, Fasano A, et al. Prothrombotic state induced by COVID-19 infection as trigger for stroke in young patients: A dangerous association. eNeurologicalSci. 2020;20:100247. DOI:10.1016/j.ensci.2020.100247Crivelli L, Palmer K, Calandri I, et al. Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis. Alzheimer’s Dement. 2022;4(10):e2130645. DOI:10.1002/alz.12644Becker JH, Lin JJ, Doernberg M, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021;4(10):e2130645. DOI:10.1001/jamanetworkopen.2021.30645Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. E Clinical Medicine. 2021;39:101044. DOI:10.1016/j.eclinm.2021.101044Alonso-Lana S, Marquié M, Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals with Dementia. Front Aging Neurosci. 2020;12:588872. DOI:10.3389/fnagi.2020.588872de Graaf MA, Antoni ML, Ter Kuile MM, et al. Short-term outpatient follow-up of COVID-19 patients: a multidisciplinary approach. E Clinical Medicine. 2021;32:100731. DOI:10.1016/j.eclinm.2021.100731Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93-135. DOI:10.1016/j.bbi.2021.12.020Stallmach A, Kesselmeier M, Bauer M, et al. Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation? Infection. 2022;46:39-48. DOI:10.1007/s15010-021-01733-3Miskowiak K, Johnsen S, Sattler S, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48. DOI:10.1016/j.euroneuro.2021.03.019Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397:220-32. DOI:10.1016/S0140-6736(20)32656-8Serrano-Castro PJ, Garzón-Maldonado FJ, Casado-Naranjo I, et al. The cognitive and psychiatric subacute impairment in severe Covid-19. Sci Rep. 2022;12:3563. DOI:10.1038/s41598-022-07559-9Undurraga EA, Chowell G, Mizumoto K. COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March–August 2020. Infect Dis Poverty. 2021;10:11. DOI:10.1186/s40249-020-00785-1Goujon A, Natale F, Ghio D, et al. Age, gender, and territory of COVID-19 infections and fatalities. Luxembourg: Publications Office of the European Union, 2020. DOI:10.2760/838390Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. The Journals of Gerontology. 2020;75(11):2224-30. DOI:10.1093/gerona/glaa183Owolabi LF, Raafat A, Enwere OO, et al. Hemorrhagic infarctive stroke in COVID-19 patients: report of two cases and review of the literature. J Community Hosp Intern Med Perspect. 2021;11(3):322-6. DOI:10.1080/20009666.2021.1883814Nalugo M, Schulte LJ, Masood MF, Zayed MA. Microvascular Angiopathic Consequences of COVID-19. Front Cardiovasc Med. 2021;8:26. DOI:10.3389/fcvm.2021.636843Lara B, Carnes A, Dakterzada F, et al. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID-19 lockdown. Eur J Neurol. 2020;27:1744-7. DOI:10.1111/ene.14339Nakamura ZM, Nash RP, Laughon SL, Rosenstein DL. Neuropsychiatric Complications of COVID-19. Curr Psychiatry Rep. 2021;23(5):25. DOI:10.1007/s11920-021-01237-9Iodice F, Cassano V, Rossini PM. Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer’s disease populations. Neurol Sci. 2021;42(2):455-65. DOI:10.1007/s10072-020-04902-8Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170. DOI:10.1186/s13195-020-00744-wFotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimer’s Dis. 2020;76:3-19. DOI:10.3233/JAD-200581Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med Sci Monit. 2020;26(7):4016-26. DOI:10.12659/MSM.928996Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. The Journals of Gerontology. 2020;75(11):2231-2. DOI:10.1093/gerona/glaa131Douaud G, Lee S, Alfaro-Almagro F, et al. Brain imaging before and after COVID-19 in UK Biobank. medRxiv Prepr Serv Heal Sci. 2021;06(11). DOI:10.1101/2021.06.11.21258690Государственный реестр лекарственных средств Минздрава России. Режим доступа: https://grls.rosminzdrav.ru. Ссылка активна на 25.03.2022. [Gosudarstvennyi reestr lekarstvennykh sredstv Minzdrava Rossii. Available at: https://grls.rosminzdrav.ru. Accessed: 25.03.2022 (in Russian)].Остроумова О.Д., Кочетков А.И., Остроумова Т.М., Клепикова М.В. Потенциал ницерголина в условиях полиморбидности и когнитивных нарушений (клинический пример). Медицинский алфавит. 2020;1(19):11-8 [Ostroumova OD, Kochetkov AI, Ostroumova TM, Klepikova MV. Potential of nicergoline in polymorbidity and cognitive impairment (clinical case). Medical alphabet. 2020;1(19):11-8 (in Russian)]. DOI:10.33667/2078-5631-2020-19-11-18Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;4. DOI:10.1002/14651858.CD003159Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014;4(7):e005090. DOI:10.1136/bmjopen-2014-005090Boulu P. Effects du Sermion® sur les troubles mn.esiques et les fonctions de la vie de relation. Tempo medical. 1990;397:24-7.Sibilio P, Bini S, Fiscon G, et al. In silico drug repurposing in COVID-19: A network-based analysis. Biomed Pharmacother. 2021;142:111954. DOI:10.1016/j.biopha.2021.111954Rose L, Graham L, Koenecke A, et al. The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. Front Med. 2021;8. DOI:10.3389/fmed.2021.637647Luo P, Liu D, Li J. Epinephrine use in COVID-19: friend or foe? Eur J Hosp Pharm. 2021;28(1):e1. DOI:10.1136/ejhpharm-2020-002295Navan C. Possible Drug Candidates for COVID-19. chemRxiv. 2020. Available at: https://chemrxiv.org/articles/Possible_Drug_Candidates_for_COVID-19/11985231. Accessed: 25.03.2022.Rejdak K, Karbowniczek A, Białecka M, et al. Treatment in post-COVID syndrome – nicergoline as the therapeutic potential in reduction symptoms of COVID brain fog. Medycyna Faktów. 2021;14:294-302. DOI:10.24292/01.MF.0321.12Ikemoto K. Multi-Particulate High Intensity of Brain MRI in 30’s Male Heavy Smoker Suicidal Attempt Case following Mild COVID-19 Pneumonia. Adv Case Stud. 2021;3(2):e1. DOI:10.31031/AICS.2021.03.000558